Marine organisms represent a new extensive source for bioactive molecules. They have the potential to provide new therapeutic alternatives to treat human diseases. In this paper, we describe and discuss a variety of isolated and semisynthetic molecules obtained from marine sources. These compounds are in phase II, phase III and at the commercialization stage of new drug development. A description of the mechanism of action, dosage used and side effects are also reported. The positive results obtained from these studies have triggered the development of new studies to evaluate the prospects for utilization of marine organisms.
Yasuhara-BellJ, LuY. (2010) Marine compounds and their antiviral activities. Antiviral Research, 86, 231-240.
2.
VosmaerGcj, BidderGP, Vosmaer-RoëllCS. (1928) Bibliography of sponges 1551-1913. University Press, Cambridge. 234 p.
3.
ThompsonDW. (1885) A bibliography of protozoa, sponges, cœlenterata, and worms: Including also the polyzoa, brachiopoda and tunicata, for the years 1861-1883. University Press, Cambridge. 284 p.
4.
KrukenbergCfw. (1880) Küsten der Adria, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath II, 1-273.
5.
KrukenbergCfw. (1880) Studien zu Tunis; Mentone und Palermo, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath III, 1-192.
6.
KrukenbergCfw. (1880) Küsten der Adria, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath I, 1-108.
7.
KrukenbergCfw. (1882) Die Floridine der Eenieren, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath 3, 3560-3640.
8.
KrukenbergCfw. (1882) Ueber die melanotischen Verfarbungen der Uranidine, experimentelle Untersuchungen. VergleichendPhysiologische Studien, Bath 3, 4111-4156.
9.
KrukenbergCfw. (1882) Die Lipochrome der Spongien, experimentelle Untersuchungen. Vergleichend-Physiologische Studien, Bath 3, 108085-108115.
10.
DoréeC. (1909) The occurrence and distribution of cholesterol and allied bodies in the animal kingdom. Biochemical Journal, 4, 72–106.
11.
HenzeM. (1904) Spongosterin, eine cholesterinartige Substanz aus Suberites domuncula, und seine angebliche Beziehung zum Lipochrom dieses Tieres. Hoppe-Seyler's Zeitschrift für physiologische Chemie, 41, 109-124.
12.
HenzeM. (1908) Über Spongosterin, das Cholesterin aus Suberites domuncula. Hoppe-Seyler's Zeitschrift für physiologische Chemie, 55, 427-432.
TaftC. (1945) Poisonous marine animals. Texas Reports on Biology and Medicine, 10, 43-55.
15.
EmersonG, TaftC. (1945) Pharmacologically active agents from the sea. Texas Reports on Biology and Medicine, 3, 302-338.
16.
PrattR, MautnerH, GardnerGM, ShaYH, DufrenoyJ. (1951) Report on antibiotic activity of seaweed extracts. Journal of the American Pharmaceutical Association, 40, 575-579.
17.
BurkholderPR, BurkholderLM, AlmodóvarLR. (1960) Antibiotic activity of some marine algae of Puerto Rico. Botanica Marina, 2, 149-156.
18.
BergmannW, FeeneyRJ. (1951) Contributions to the study of marine products. XXXII. The nucleosides of sponges I. The Journal of Organic Chemistry, 16, 981-987.
19.
StahlE. (1956) Thin-layer chromatography; methods, influencing factors and an example of its use. Pharmazie, 11, 633-637.
20.
StahlE. (1958) Thin-layer chromatography. II. Standardization; detection; documentation and application. Chemiker Zeitung, 82, 323-329.
21.
BergmannW, BurkeDC. (1955) Contributions to the study of marine products. XXXIX. The nucleosides of sponges. III. Spongothymidine and spongouridine. The Journal of Organic Chemistry, 20, 1501-1507.
22.
EvansJS, MusserEA, MengelGD, ForsbladKR, HunterJH. (1961) Antitumor activity of 1-beta-D-arainofuranosylcytosine hydrochloride. Proceedings of the Society for Experimental Biology and Medicine, 106, 350-353.
23.
CohenSS. (1963) Sponges, cancer chemotherapy, and cellular aging. Perspectives in Biology and Medicine, 6, 215-227.
24.
HorwitzJP, ChuaJ, NoelM. (1964) Nucleosides. V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl)thymine1,2. The Journal of Organic Chemistry, 29, 2076-2078.
25.
DixonRL, AdamsonRH. (1965) Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC-63878). Cancer Chemotherapy Reports. Part 1, 48, 11-16.
26.
HeidelbergerC. (1967) Cancer chemotherapy with purine and pyrimidine analogues. Annual Review of Pharmacology, 7, 101-124.
27.
MayerAms. (1999) Marine pharmacology in 1998: Antitumor and cytotoxic compounds. The Pharmacologist, 41, 159-164.
28.
MayerAms, GustafsonKR. (2003) Marine pharmacology in 2000: Antitumor and cytotoxic compounds. International Journal of Cancer, 105, 291-299.
29.
MayerAms, GustafsonKR. (2004) Marine pharmacology in 2001-2: Antitumor and cytotoxic compounds. European Journal of Cancer, 40, 2676-2704.
30.
MayerAms, GustafsonKR. (2006) Marine pharmacology in 2003-2004: Antitumour and cytotoxic compounds. European Journal of Cancer, 42, 2241-2270.
31.
MayerAms, GustafsonKR. (2008) Marine pharmacology in 2005-2006: Antitumour and cytotoxic compounds. European Journal of Cancer, 44, 2357-2387.
32.
MayerAms, HamannM. (2004) Marine pharmacology in 2000: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action. Marine Biotechnology, 6, 37-52.
33.
MayerAms, HamannMT. (2002) Marine pharmacology in 1999: compounds with antibacterial, anticoagulant, antifungal, anthelmintic, anti-inflammatory, antiplatelet, antiprotozoal and antiviral activities affecting the cardiovascular, endocrine, immune and nervous systems, and other miscellaneous mechanisms of action. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 132, 315-339.
34.
MayerAms, HamannMT. (2005) Marine pharmacology in 2001-2002: Marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 140, 265-286.
35.
MayerAms, LehmannVkb. (2000) Marine pharmacology in 1998: Marine compounds with antibacterial, anticoagulant, anti-inflammatory, anthelmintic, antiplatelet, antiprotozoal, and antiviral activities; with actions on the cardiovascular, endocrine, immune, and nervous systems; and other miscellaneous mechanisms of action. The Pharmacologist, 42, 62-69.
36.
MayerAms, LehmannVkb. (2001) Marine pharmacology in 1999: Antitumor and cytotoxic compounds. Anticancer Research, 21, 2489-2500.
37.
MayerAms, RodríguezAD, BerlinckRgs, FusetaniN. (2011) Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 153, 191-222.
38.
MayerAms, RodríguezAD, BerlinckRgs, HamannMT. (2007) Marine pharmacology in 2003-4: Marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 145, 553-581.
39.
MayerAms, RodríguezAD, BerlinckRgs, HamannMT. (2009) Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochimica et Biophysica Acta, 1790, 283-308.
EridaniS. (1972) Cytarabine: mechanism of action and clinical application. Haematologica, 57, 341-358.
42.
FreiE, BickersJN, HewlettJS, LaneM, LearyWV, TalleyRW. (1969) Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Research, 29, 1325-1332.
43.
SweetmanSC. (2007) Martindale: the complete drug reference. Pharmaceutical Press, London. 3322 p.
44.
National Institutes of Health, NIH. (1983) Recommendations for the safe handling of parenteral antineoplastic drugs. NIH publication, Washington D.C. NIH83-2621.
45.
JonesRB, FrankR, MassT. (1983) Safe handling of chemotherapeutic agents: a report from The Mount Sinai Medical Center. CA: A Cancer Journal for Clinicians, 33, 258-263.
46.
SchimmerAD, EsteyEH, BorthakurG, CarterBZ, SchillerGJ, TallmanMS, AltmanJK, KarpJE, KassisJ, HedleyDW, BrandweinJ, XuW, MakDH, LacasseE, JacobC, MorrisSJ, JolivetJ, AndreeffM. (2009) Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Journal of Clinical Oncology, 27, 4741-4746.
47.
YaoYY, ZhuQ, ZouLF, DouHJ, ChenYM, TangY, HuJP. (2009) Clinical study on fludarabin combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia. Journal of Experimental Hematology, 17, 774-776.
48.
CiminoG, De RosaS, De StefanoS. (1984) Antiviral agents from a gorgonian, Eunicella cavolini. Cellular and Molecular Life Sciences, 40, 339-340.
OliveraB, GrayW, ZeikusR, McintoshJ, VargaJ, RivierJ, De SantosV, CruzL. (1985) Peptide neurotoxins from fish-hunting cone snails. Science, 230, 1338-1343.
54.
LópezJ. (2001) Conotoxinas. Spira, 1, 7-11.
55.
LawsonE, WallaceM. (2010) Current developments in intraspinal agents for cancer and noncancer pain. Current Pain and Headache Reports, 14, 8-16.
56.
SchmidtkoA, LötschJ, FreynhagenR, GeisslingerG. (2010) Ziconotide for treatment of severe chronic pain. The Lancet, 375, 1569-1577.
57.
SigelM, WellhamL, LichterW, DudeckL, GargusJ, LucasL. (1969) Food-Drugs from the Sea. YoungkenHW (Ed.), Marine Technology Society, Washington DC.281-295.
58.
RinehartKL. (1990) Ecteinascidin-729, Ecteinascidin-743, Ecteinascidin-745, Ecteinascidin-759a, Ecteinascidin-759b, and Ecteinascidin-770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. Journal of Organic Chemistry, 55, 4512-4515.
59.
WrightAE, ForleoDA, GunawardanaGP, GunasekeraSP, KoehnFE, McconnellOJ. (1990) Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. The Journal of Organic Chemistry, 55, 4508-4512.
60.
CuevasC, FranceschA. (2009) Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Natural Product Reports, 26, 322-337.
61.
CoreyEJ, GinDY, KaniaRS. (1996) Enantioselective total synthesis of ecteinascidin 743. Journal of the American Chemical Society, 118, 9202-9203.
62.
CuevasC, PérezM, MartínMJ, ChicharroJL, Fernández-RivasC, FloresM, FranceschA, GallegoP, ZarzueloM, De LaCalle F, GarcíaJ, PolancoC, RodríguezI, ManzanaresI. (2000) Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Organic Letters, 2, 2545-2548.
63.
[No authors listed]. (2006) Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs in R&D, 7, 317-328.
64.
AuneGJ, FurutaT, PommierY. (2002) Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anti-Cancer Drugs, 13, 545-555.
65.
BurgoyneDL, AndersenRJ, AllenTM. (1992) Contignasterol, a highly oxygenated steroid with the unnatural 14-beta configuration from the marine sponge Petrosia contignata Thiele, 1899. The Journal of Organic Chemistry, 57, 525-528.
66.
YangL, AndersenRJ. (2002) Absolute configuration of the antiinflamatory sponge natural product contignasterol. Journal of Natural Products, 65, 1924-1926.
67.
TakeiM, BurgoyneDL, AndersenRJ. (1994) Effect of contignasterol on histamine release induced by anti-immunoglobuline from rat peritoneal mast cells. Journal of Pharmaceutical Sciences, 83, 1234-1235.
68.
BramleyAM, LanglandsJM, JonesAK, BurgoyneDL, LiY, AndersenRJ, SalariH. (1995) Effects of IZP-94005 (contignasterol) on antigen-induced bronchial responsiveness in ovalbumin-sensitized guinea-pigs. British Journal of Pharmacology, 115, 1433–1438.
69.
ShenY, BurgoyneDL. (2002) Efficient synthesis of IPL576,092: A novel anti-asthma agent. The Journal of Organic Chemistry, 67, 3908-3910.
70.
LeonardP, SurS. (2002) Asthma: future directions. Medical Clinics of North America, 86, 1131-1156.
71.
GrossH, KönigG. (2006) Terpenoids from marine organisms: Unique structures and their pharmacological potential. Phytochemistry Reviews, 5, 115-141.
72.
LanglandsJ, LaforceC. (2006) The effect of IPL512,602 in patients with mild-moderate persistent asthma (NEAT study). Proceedings of the American Thoracic Society, 3, 80 (Abstr Suppl).
73.
RinehartKL, GloerJB, CookJC, MizsakSA, ScahillTA. (1981) Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. Journal of the American Chemical Society, 103, 1857-1859.
74.
RinehartKJr, GloerJ, HughesRJr, RenisH, McgovrenJ, SwynenbergE, StringfellowD, KuentzelS, LiL. (1981) Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science, 212, 933-935.
75.
HossainMB, Van DerHelm D, AntelJ, SheldrickGM, SandujaSK, WeinheimerAJ. (1988) Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide. Proceedings of the National Academy of Sciences of the United States of America, 85, 4118-4122.
76.
CrewsCM, CollinsJL, LaneWS, SnapperML, SchreiberSL. (1994) GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. Journal of Biological Chemistry, 269, 15411-15414.
77.
MengL, SinN, CrewsCM. (1998) The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase. Biochemistry, 37, 10488-10492.
78.
VeraMD, JoulliéMM. (2002) Natural products as probes of cell biology: 20 years of didemnin research. Medicinal Research Reviews, 22, 102-145.
79.
KucukO, YoungML, HabermannTM, WolfBC, JimenoJ, CassilethPA. (2000) Phase II trial of didemnin B in previously treated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group (ECOG) study. American Journal of Clinical Oncology, 23, 273-277.
80.
RinehartKL, Lithgow-BertelloniA,(1990) Dehydrodidemnin B. US Patent RE39887. 23p.
81.
JimenoJ. (2002) A clinical armamentarium of marine-derived anticancer compounds. Anti-Cancer Drugs, Suppl 1, 15-19.
82.
JimenoJ, López-MartínJA, Ruiz-CasadoA, IzquierdoMA, ScheuerPJ, RinehartK. (2004) Progress in the clinical development of new marine-derived anticancer compounds. Anti-Cancer Drugs, 15, 321-329.
83.
BrogginiM, MarchiniSV, GallieraE, BorsottiP, TarabolettiG, ErbaE, SironiM, JimenoJ, FairclothGT, GiavazziR, DincalciM. (2003) Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 17, 52-59.
84.
Muñoz-AlonsoMJ, González-SantiagoL, MartínezT, LosadaA, GalmariniCM, MuñozA. (2009) The mechanism of action of plitidepsin. Current Opinion in Investigational Drugs, 10, 536-542.
85.
BiscardiM, CaporaleR, BalestriF, GavazziS, JimenoJ, GrossiA. (2005) VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Annals of Oncology, 16, 1667-1674.
86.
MortonCL, HoughtonPJ, GorlickR, KolbEA, LockR, CarolH, KeirST, ReynoldsCP, KangMH, MarisJM, BillupsC, SmithMA. (2009) Initial testing of aplidin by the pediatric preclinical testing program. Pediatric Blood & Cancer, 53, 509-512.
LeTourneau C, FaivreS, CiruelosE, DomínguezMJ, López-MartínJA, IzquierdoMA, JimenoJ, RaymondE. (2010) Reports of clinical benefit of plitidepsin (aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. American Journal of Clinical Oncology, 33, 132-136.
89.
SchöffskiP, GuillemV, GarciaM, RiveraF, TaberneroJ, CullellM, Lopez-MartinJA, PollardP, DumezH, Garcia DelMuro X, Paz-AresL. (2009) Phase II randomized study of plitidepsin (aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Marine Drugs, 7, 57-70.
90.
PettitGR, OdeRH, HeraldCL, Von DreeleRB, MichelC. (1976) Antineoplastic agents. 46. The isolation and structure of dolatriol. Journal of the American Chemical Society, 98, 4677-4678.
91.
PettitGR, KamanoY, FujiiY, HeraldCL, InoueM, BrownP, GustD, KitaharaK, SchmidtJM, DoubekDL, MichaelC. (1981) Marine animal biosynthetic constituents for cancer chemotherapy. Journal of Natural Products, 44, 482-485.
92.
HarriganGG, LueschH, YoshidaWY, MooreRE, NagleDG, PaulVJ, MooberrySL, CorbettTH, ValerioteFA. (1998) Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. Journal of Natural Products, 61, 1075-1077.
93.
PettitGR, KamanoY, HeraldCL, TuinmanAA, BoettnerFE, KizuH, SchmidtJM, BaczynskyjL, TomerKB, BontemsRJ. (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. Journal of the American Chemical Society, 109, 6883-6885.
94.
BaiRL, PettitGR, HamelE. (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and Vinca alkaloid sites. Journal of Biological Chemistry, 265, 17141-17149.
95.
JordanA, HadfieldJA, LawrenceNJ, McgownAT. (1998) Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Medicinal Research Reviews, 18, 259-296.
96.
PettitGR. (1989) The absolute-configuration and synthesis of natural (-)-Dolastatin-10. Journal of the American Chemical Society, 111, 5463-5465.
97.
MaddenT, TranHT, BeckD, HuieR, NewmanRA, PusztaiL, WrightJJ, AbbruzzeseJL. (2000) Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clinical Cancer Research, 6, 1293-1301.
98.
VaishampayanU, GlodeM, DuW, KraftA, HudesG, WrightJ, HussainM. (2000) Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clinical Cancer Research, 6, 4205-4208.
99.
MargolinK, LongmateJ, SynoldTW, GandaraDR, WeberJ, GonzalezR, JohansenMJ, NewmanR, BarattaT, DoroshowJH. (2001) Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California cancer consortium. Investigational New Drugs, 19, 335-340.
100.
KobayashiM, NatsumeT, TamaokiS, WatanabeJI, AsanoH, MikamiT, MiyasakaK, MiyazakiK, GondoM, SakakibaraK, TsukagoshiS. (1997) Antitumor activity of TZT-1027, a novel doiastatin 10 derivative. Cancer Science, 88, 316-327.
101.
PatelS, KeohanML, SaifMW, RushingD, BaezL, FeitK, DejagerR, AndersonS. (2006) Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer, 107, 2881-2887.
102.
RielyGJ, GadgeelS, RothmanI, SaidmanB, SabbathK, FeitK, KrisMG, RizviNA. (2007) A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer, 55, 181-185.
103.
YamamotoN, AndohM, KawaharaM, FukuokaM, NiitaniH. (2009) Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Science, 100, 316-321.
104.
PettitGR, KamanoY, DufresneC, CernyRL, HeraldCL, SchmidtJM. (1989) Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. The Journal of Organic Chemistry, 54, 6005-6006.
105.
Cruz-MonserrateZ, MullaneyJT, HarranPG, PettitGR, HamelE. (2003) Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel–Dreyer chromatography. European Journal of Biochemistry, 270, 3822-3828.
106.
SmythJ, BoneterreME, SchellensJ, CalvertH, GreimG, WandersJ, HanauskeA. (2001) Activity of the dolastatin analogue, LU103793, in malignant melanoma. Annals of Oncology, 12, 509-511.
107.
NewmanDJ, CraggGM. (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. Journal of Natural Products, 67, 1216-1238.
108.
MitaAC, HammondLA, BonatePL, WeissG, MccreeryH, SyedS, GarrisonM, ChuQsc, DebonoJS, JonesCB, WeitmanS, RowinskyEK. (2006) Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clinical Cancer Research, 12, 5207-5215.
109.
RayA, OkounevaT, MannaT, MillerHP, SchmidS, ArthaudL, LuduenaR, JordanMA, WilsonL. (2007) Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Research, 67, 3767-3776.
110.
KilburnL, BonateP, BlaneyS, McguffeyL, NuchternJ, DauserR, ThompsonP, GibsonB, BergS. (2009) Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemotherapy and Pharmacology, 64, 335-340.
111.
McdermottDF, HershE, WeberJ, StephensonJ, CunninghamCC, EbbinghausS, ThompsonJ, O'dayS, WeitmanS, HammondL. (2005) ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: Phase II experience. Journal of Clinical Oncology, 23, 7556 (Abstr Suppl).
112.
HirataY, UemuraD. (1986) Halichondrins - antitumor polyether macrolides from a marine sponge. Pure and Applied Chemistry, 58, 701-710.
113.
AicherTD, BuszekKR, FangFG, ForsythCJ, JungSH, KishiY, MatelichMC, ScolaPM, SperoDM, YoonSK. (1992) Total synthesis of halichondrin B and norhalichondrin B. Journal of the American Chemical Society, 114, 3162-3164.
114.
BaiRL, PaullKD, HeraldCL, MalspeisL, PettitGR, HamelE. (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. Journal of Biological Chemistry, 266, 15882-15889.
115.
FodstadO, BreistølK, PettitGR, ShoemakerRH, BoydMR. (1996) Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts. Journal of Experimental Therapeutics and Oncology, 1, 119-125.
116.
WangY, HabgoodGJ, ChristWJ, KishiY, LittlefieldBA, YuMJ. (2000) Structure-activity relationships of Halichondrin B analogues: modifications at C30-C38. Bioorganic & Medicinal Chemistry Letters, 10, 1029-1032.
117.
TowleMJ, SalvatoKA, BudrowJ, WelsBF, KuznetsovG, AalfsKK, WelshS, ZhengW, SeletskyBM, PalmeMH, HabgoodGJ, SingerLA, DipietroLV, WangY, ChenJJ, QuincyDA, DavisA, YoshimatsuK, KishiY, YuMJ, LittlefieldBA. (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Research, 61, 1013-1021.
118.
JacksonKL, HendersonJA, PhillipsAJ. (2009) The halichondrins and E7389. Chemical Reviews, 109, 3044-3079.
119.
HamannMT, ScheuerPJ. (1993) Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. Journal of the American Chemical Society, 115, 5825-5826.
120.
SewellJM, MayerI, LangdonSP, SmythJF, JodrellDI, GuichardSM. (2005) The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines. European Journal of Cancer, 41, 1637-1644.
121.
PardoB, Paz-AresL, TaberneroJ, CiruelosE, GarcíaM, SalazarR, LópezA, BlancoM, NietoA, JimenoJ, IzquierdoMA, TrigoJM. (2008) Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clinical Cancer Research, 14, 1116-1123.
122.
SalvadorMA, EnriqueE, JordiR, Juan JoséLópez L, JoséLuis M, LorenzoAlonso C, ArrateP, AdnanT, LuisPA. (2009) Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. European Journal of Cancer, 45, 732-735.
ProvencioM, SánchezA, GasentJ, GómezP, RosellR. (2009) Cancer treatments: Can we find treasures at the bottom of the sea? Clinical Lung Cancer, 10, 295-300.
125.
PettitGR, HeraldCL, DoubekDL, HeraldDL, ArnoldE, ClardyJ. (1982) Isolation and structure of bryostatin 1. Journal of the American Chemical Society, 104, 6846-6848.
126.
SchaufelbergerDE, KoleckMP, BeutlerJA, VatakisAM, AlvaradoAB, AndrewsP, MarzoLV, MuschikGM, RoachJ, RossJT, LebherzWB, ReevesMP, EberweinRM, RodgersLL, TestermanRP, SnaderKM, ForenzaS. (1991) The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. Journal of Natural Products, 54, 1265-1270.
127.
MendolaD. (2003) Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics. Biomolecular Engineering, 20, 441-458.
128.
WenderPA, CribbsCM, KoehlerKF, SharkeyNA, HeraldCL, KamanoY, PettitGR, BlumbergPM. (1988) Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proceedings of the National Academy of Sciences of the United States of America, 85, 7197-7201.
129.
MutterR, WillsM. (2000) Chemistry and clinical biology of the bryostatins. Bioorganic & Medicinal Chemistry, 8, 1841-1860.
130.
WinegardenJD, MauerAM, GajewskiTF, HoffmanPC, KraussS, RudinCM, VokesEE. (2003) A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer, 39, 191-196.
131.
MolinskiTF, DalisayDS, LievensSL, SaludesJP. (2009) Drug development from marine natural products. Nature Reviews. Drug Discovery, 8, 69-85.
132.
KhanTK, NelsonTJ, VermaVA, WenderPA, AlkonDL. (2009) A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Aβ-induced biomarker abnormality on cultured fibroblasts. Neurobiology of Disease, 34, 332-339.
133.
Ayral-KaloustianS, ZaskA. (2005) Taltobulin. Drugs of the Future, 30, 254-260.
134.
HadaschikBA, EttingerS, SoweryRD, ZoubeidiA, AndersenRJ, RobergeM, GleaveME. (2008) Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. International Journal of Cancer, 122, 2368-2376.
135.
NiuC, HoDM, ZaskA, Ayral-KaloustianS. (2010) Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. Bioorganic & Medicinal Chemistry Letters, 20, 1535-1538.
136.
D'agostinoG, Del CampoJ, MelladoB, IzquierdoM, MinarikT, CirriL, MariniL, Perez-GraciaJ, ScambiaG. (2006) A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. International Journal of Gynecological Cancer, 16, 71-76.
137.
FreedmanR, OlincyA, BuchananRW, HarrisJG, GoldJM, JohnsonL, AllensworthD, Guzman-BonillaA, ClementB, BallMP, KutnickJ, PenderV, MartinLF, StevensKE, WagnerBD, ZerbeGO, SotiF, KemWR. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. American Journal of Psychiatry, 165, 1040-1047.
138.
StevensKE, CornejoB, AdamsCE, ZhengL, YonchekJ, HoffmanKL, ChristiansU, KemWR. (2010) Continuous administration of a selective α-7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Research, 1352, 140-146.
139.
LealJfm, García-HernándezV, MoneoV, DomingoA, Bueren-CalabuigJA, NegriA, GagoF, Guillén-NavarroMJ, AvilésP, CuevasC, García-FernándezLF, GalmariniCM. (2009) Molecular pharmacology and antitumor activity of Zalypsis® in several human cancer cell lines. Biochemical Pharmacology, 78, 162-170.
140.
SinghAV, PalladinoMA, LloydGK, PottsBC, ChauhanD, AndersonKC. (2010) Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. British Journal of Haematology, 149, 550-559.
141.
KuznetsovG, TendykeK, TowleMJ, ChengH, LiuJ, MarshJP, SchillerSer, SpyveeMR, YangH, SeletskyBM, ShafferCJ, MarceauV, YaoY, SuhEM, CampagnaS, FangFG, KowalczykJJ, LittlefieldBA. (2009) Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Molecular Cancer Therapeutics, 8, 2852-2860.
